What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: In France, mumps surveillance is conducted in primary care by the Sentinelles network, the National Reference Centre for Measles, Mumps and Rubella and Santé publique France.
AIM: The objective of this study was to estimate the incidence of suspected mumps in general practice, the proportion of laboratory confirmed cases and the factors associated with a virological confirmation.
METHODS: General practitioners (GPs) participating in the Sentinelles network should report all patients with suspected mumps according to a clinical definition in case of parotitis and a serological definition in case of clinical expression without parotitis. All suspected mumps cases reported between January 2014 and December 2020 were included. A sample of these cases were tested by real time reverse transcriptase polymerase chain reaction (RT-PCR) for mumps biological confirmation.
RESULTS: A total of 252 individuals with suspected mumps were included in the study. The average annual incidence rate of suspected mumps in general practice in France between 2014 and 2020 was estimated at 11 cases per 100,000 population [CI95%: 6-17]. A mumps confirmation RT-PCR test was performed on 146 cases amongst which 17 (11.5 %) were positive. Age (between 20 and 29 years old), the presence of a clinical complication and an exposure to a suspected mumps case within the 21 days prior the current episode were associated with a mumps biological confirmation.
CONCLUSION: If these results confirm the circulation of mumps virus in France, they highlight the limits of a surveillance without a systematic laboratory confirmation in highly immunized populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 5 vom: 15. Feb., Seite 1065-1070 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prévot-Monsacré, Pol [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diagnosis |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2023.12.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365833118 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365833118 | ||
| 003 | DE-627 | ||
| 005 | 20240229154722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2023.12.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM365833118 | ||
| 035 | |a (NLM)38092609 | ||
| 035 | |a (PII)S0264-410X(23)01451-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prévot-Monsacré, Pol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: In France, mumps surveillance is conducted in primary care by the Sentinelles network, the National Reference Centre for Measles, Mumps and Rubella and Santé publique France | ||
| 520 | |a AIM: The objective of this study was to estimate the incidence of suspected mumps in general practice, the proportion of laboratory confirmed cases and the factors associated with a virological confirmation | ||
| 520 | |a METHODS: General practitioners (GPs) participating in the Sentinelles network should report all patients with suspected mumps according to a clinical definition in case of parotitis and a serological definition in case of clinical expression without parotitis. All suspected mumps cases reported between January 2014 and December 2020 were included. A sample of these cases were tested by real time reverse transcriptase polymerase chain reaction (RT-PCR) for mumps biological confirmation | ||
| 520 | |a RESULTS: A total of 252 individuals with suspected mumps were included in the study. The average annual incidence rate of suspected mumps in general practice in France between 2014 and 2020 was estimated at 11 cases per 100,000 population [CI95%: 6-17]. A mumps confirmation RT-PCR test was performed on 146 cases amongst which 17 (11.5 %) were positive. Age (between 20 and 29 years old), the presence of a clinical complication and an exposure to a suspected mumps case within the 21 days prior the current episode were associated with a mumps biological confirmation | ||
| 520 | |a CONCLUSION: If these results confirm the circulation of mumps virus in France, they highlight the limits of a surveillance without a systematic laboratory confirmation in highly immunized populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a General practice | |
| 650 | 4 | |a Mumps | |
| 650 | 4 | |a Real-time polymerase chain reaction | |
| 650 | 4 | |a Sentinel surveillance | |
| 650 | 7 | |a Measles-Mumps-Rubella Vaccine |2 NLM | |
| 700 | 1 | |a Hamaide-Defrocourt, Florent |e verfasserin |4 aut | |
| 700 | 1 | |a Guyonvarch, Ophélie |e verfasserin |4 aut | |
| 700 | 1 | |a Masse, Shirley |e verfasserin |4 aut | |
| 700 | 1 | |a Souty, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Mamou, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hamel, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Antona, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Mathieu, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Vasseur, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Lévy-Bruhl, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Baroux, Noémie |e verfasserin |4 aut | |
| 700 | 1 | |a Rossignol, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Vaillant, Laetitia |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrisi, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Hanslik, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Dina, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchon, Thierry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 5 vom: 15. Feb., Seite 1065-1070 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:5 |g day:15 |g month:02 |g pages:1065-1070 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2023.12.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 5 |b 15 |c 02 |h 1065-1070 | ||